Chongdeok Park joined KOLON Pharma, one of leading Korea based Pharmaceutical companies and is responsible for development in R&D, including portfolio management, external R&D Collaboration, medical affairs, regulatory affairs, market access and business development. Prior to Kolon Pharma, he held positions of responsibility focused on the development of branded generics with Phase I and III clinical programs at Alvogen, emerging global generics company. He served as Chief Operation Officer at early-stage Biotech Company in US, operating early-stage clinical programs. He also served as a global crew leader of Hepatitis B development program and Launch Readiness in Novartis and was responsible for Bone Marrow Transplantation clinical development program in Asia area, at Schering AG.
Currently, Chongdeok is also an independent consultant, helping several mid-size Investment Banks to evaluate the pipelines of small to mid-staged biotech firms in Asia and US. Chongdeok Park received BS in Pharmacy and Master of Pharmacy from Sungkyunkwan University in Korea, and his MBA from the Tepper School of Business at Carnegie Mellon University.